With the mission to detect cancer when it is still curable, SeekInCare has been developed as a pan cancer detection test that takes a panoramic view of blood cell-free cancer signatures and a multi-omics approach incorporating genomic and epigenetic alterations in conjunction with clinically validated protein biomarkers. Equipped with proprietary AI- and big data-driven CRS algorithm, SeekInCare exhibits superior effectiveness to detect dozens of cancer types at high specificity. SeekInCare has been launched as a lab developed test (LDT) in China since late 2018. SeekInCare is intend to use for the individuals with elevated risks of cancer such as smoking, chronic hepatitis, aging, etc., in conjunction with the approved conventional single cancer type screening tests.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2018
- Website
- www.seekincancer.com/
Categories
Only accessible to MedStartr community members.
Join nowWhat do you think of SeekIn (思勤医疗)?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now